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Breast cancer 3.a Identified breast CSC markers
Breast cancer was the first solid tumor identified to have a population of tumor cells with an inherent highly tumorigenic quality. These cells were termed tumor propagating cells at the time, and are now more commonly known as breast CSCs. In 2003, Al-Hajj et al. performed experiments akin to the leukemia studies discussed above (Bonnet and Dick, 1997; Lapidot et al., 1994) , and isolated sub-tumor cell populations based on cell surface marker expression (Al-Hajj et al., 2003) . The group showed that as few as 10 2 CD24 -/low CD44 + breast tumor cells could re-capitulate the tumor with much of its original heterogeneity (Al-Hajj et al., 2003) . The authors proposed that not all CD24 -/low CD44 + cells were CSCs but that the breast CD24 -/low CD44 + population was enriched for CSCs. It was hypothesized that if additional breast CSC markers were identified it may be possible to isolate and even more highly tumorigenic cells and initiate a tumor in xenograft from only one cell. This led to the pursuit of the identification of additional markers, both cell surface and functional. Using the same functional marker approach previously employed for leukemia (Cheung et al., 2007) , Ginestier et al. were the first to isolate CSCs from a solid tumor based on increased ALDH activity (Ginestier et al., 2007) . The researchers showed that as few as 10 2 ALDH+ breast cancer cell isolated from patients could induce tumors in immunocompromised mice. Further, in a proof of principle experiment, the researchers isolated CD24 -/low CD44 + ALDH + breast cancer cells and were able to induce tumors in immunocompromised mice with as few as 20 injected cells. This experiment combining mulitple markers for the isolation of highly tumorigenic cells provided supportive evidence to the proposed hypothesis that identifying additional markers would lead to further enrichment of the CSC population.
In another more recent approach using a functional markers to identify novel breast CSCs, Pece et al. isolated the human normal mammary stem cells (hNMSCs) from mammary reduction surgeries by retention of a lipophillic fluorescent dye, PKH26 (Pece et al., 2010) . PKH26 stains quiescent cells, allowing for the isolation of relatively non-dividing cells from a mixed population of proliferating cells (Lanzkron et al., 1999) . From these isolated putative stem cells, Pece et al. identified a unique gene expression signature, the hNMSC signature, and applied it to published breast cancer gene expression data sets (Pece et al., 2010) . This analysis revealed that many of the genes upregulated in normal mammary stem cells were also upregulated in higher grade, aggressive breast cancers. When the authors picked a few of these upregulated genes (i.e.CD49+, DLL1 high , DNER high ) and used them as cell surface markers, they were able to identify and isolate a sub-population of highly tumorigenic cancer initiating cells from breast tumors. As such, PKH26 stain retention and CD49+DLL1 high DNER high are the most recent breast CSC markers identified. Interestingly, CD49 is a previously known normal mammary stem cell marker, and DLL1 and DNER have been connected to normal stem cell function.
3.b Breast CSC markers as prognostic indicators
CSC quantification is a proposed prognostic indicator for breast cancer. Translating this to clinical application requires immunohistological methods for identification of CSCs in fixed tumor tissue and in this respect, the data is less convincing and is summarized in Table 2 . First, for CD24 -/low CD44 + the published studies have been mixed. In 2005, Abraham et al. were the first to publish a study on the prognostic applicability of the then newly identified breast CSC markers (Abraham et al., 2005) . The authors double stained an archived panel of 122 fixed breast cancer patient tumor samples for the prevalence of CD24 -/low CD44 + . They failed to find a correlation between increased abundance of these cells and tumor progression or worse outcome, but they did note a tendency towards the development of distant metastases (Abraham et al., 2005 (Honeth et al., 2008) . Also in 2008, Mylona et al. stained a panel of 155 fixed patient tumor samples and reported that the prevalence of CD24 -/low CD44 + cells did not significantly correlate with worse prognosis. In fact, in disagreement with the CSC theory they found the opposite. Surprisingly, patient tumors with increased CD24 -/low CD44 + cells tended to manifest increased disease-free survival (Mylona et al., 2008) . Cultured cell experiments indicate that CD24 -/low CD44 + breast cancer cells are relatively more resistant to currently used therapeutics (Phillips et al., 2006) . This suggests that prevalence of CD24 -/low CD44 + cells in patient tumors is a potential measure of the susceptibility of breast cancer to certain therapeutics. If this hypothesis is true, then one would predict that post treatment, the percentage of these cells would increase as the overall bulk of the tumor is decreased. In a recent neoadjuvant immunohistological study of an archived panel of patient tumor samples before and after treatment, Aulmann et al. failed to show an increase in the frequency of CD24 -/low CD44 + cells post treatment (Aulmann et al., 2010) . In contrast, in a challenge to the theory CSC of the therapeutic resistance of these cells, the authors found that post treatment, the percentage of CD24 -/low CD44 + tumor cells decreased relative to pretreatment (Aulmann et al., 2010) . Further, the prevalence of these cells in a tumor did not correlate with the patient's response to treatment or eventual outcome (Aulmann et al., 2010 (Aulmann et al., 2010) . The results from the above described immunohistological studies evaluating the prevalence of CD24 -/low CD44 + c e l l s i n b r e a s t t u m o r s a s a r e adout for predicting the relative aggressiveness of a breast cancer do not support their use as prognostic indicators. This is surprising considering that the prevalence of CD44 + cells alone in fixed breast tumor cells was discovered to be predictive of more aggressive disease long before CD44 was identified as CSC marker (Al-Hajj et al., 2003) . CD44 is a recognized predictor of breast cancer tumor grade (a histoclinical assessment of tumor cells and accepted clinical prognostic indicator (Dalton et al., 2000) ), where patients with tumor cells expressing higher levels of CD44 membrane proteins have worse outcomes (Joensuu et al., 1993; Looi et al., 2006; McSherry et al., 2007) . In light of the undisputed correlation between CD44 + tumors and worse outcome for breast cancer patients, it seems that at least employing CD44 + as a CSC marker agrees with the proposed role of CSC in mediating cancer progression. Where the hypothesis fails is in the inclusion of CD24 as a CSC marker. Perhaps the inclusion of CD24 -/low as a criterion is not necessary and may be detrimental, at least from a diagnostic perspective. In fact, even prior to its use as a selection criterion for breast CSC isolation, increased (not decreased!) CD24 expression had been correlated with worse outcome for breast cancer patients (Athanassiadou et al., 2009; Kristiansen et al., 2003) .
With the revelation that breast CSCs could also be identified by increased ALDH activity, expression of ALDH1A1 prevalence in breast cancer tumors was assessed for prognostic applicability (Ginestier et al., 2007) . In this first analysis, ALDH1A1 expression was detected in only 30% of fixed breast cancer tumor samples (Ginestier et al., 2007) . Immunohistological staining of 577 fixed tumor specimens revealed a significant correlation between ALDH1A1 expression and higher tumor grade. While these patients also had worse outcome overall, ALDH1A1 positivity failed to correlate with cancer stage and metastasis at the time of diagnosis (Ginestier et al., 2007) . Later, in contrast, for a rare highly aggressive form of breast cancer, inflammatory breast cancer (one to five percent of all breast cancers), CharafeJauffret et al. found a significant correlation between ALDH1A1 expression and development of metastasis and worse outcome (Charafe-Jauffret et al., 2010) . However, despite this positive correlation with a rare breast cancer, others have failed to show a significant correlation with ALDH1A1 prevalence and higher tumor grade, metastasis, therapeutic resistance or outcome with breast cancer in general (Morimoto et al., 2009; Neumeister and Rimm, 2009; Resetkova et al., 2009 (Morimoto et al., 2009 ). The authors failed to find a correlation between ALDH1A1 prevalence and metastasis, but did note a non-significant trend with higher grade tumors. As well, ALDH1A1 + tumors were more likely to be ER -, Ki67 -, and HER2 + (Morimoto et al., 2009) . Also in 2009, Resetkova et al. immunostained four panels of fixed breast cancer patient panels, an adjuvantly treated series of 245 samples, a neoadjuvantly treated series of 34 samples and two series of 58 and 44 ER-PR-HER2-carcinoma samples. ALDH1A1 expression correlated significantly with basal-like HER2 + cancers, but not with other important indicators like metastasis. Interestingly, this result for ALDH1A1 was similar to the study on CD24 -/low CD44 + prevalence published by Honeth et al. who described a similar correlation between basal like breast cancers and CD24 -/low CD44 + abundance. This would suggest that there is an overlap between ALDH1A1 + and CD24 -/low CD44 + cells and supports the notion that both markers identify at least some of the same cell population (i.e. CSCs). The neoadjuvantly stained data set failed to show an enrichment of ALDH1A1 + cells post treatment, therefore not supporting the hypothesis that CSC population is resistant to currently employed therapeutics (Resetkova et al., 2009) . Interestingly, however, the authors noted an increased expression of ALDH1A1 + in the stromal tissue post treatment, but overall higher expression in the stroma was associated with better outcomes. Most recently, Neumeister et al stained a panel of 639 breast cancer for ALDH1A1, CD44 and cytokeratin . While the prevalence of all three markers together was associated with worse outcome, staining the cohort of samples for ALDH1A1 alone failed to correlate with any of the prognostic indicators (e.g. tumor grade, lymph node metastasis), nor patient outcome . Overall, the published data does not lend strong support toward the prognostic potential of ALDH1A1 or CD24 -/low CD44 + . This has led to the suggestion that other breast CSC marker need to be identified, and has resulted in some scepticism as to the validity of the existing identified markers (Neumeister and Rimm, 2009) . However, it is noted that when employed in combination, CD44 and ALDH1A1 prevalence did predict outcome for breast cancer patients , suggesting that the key may be using the CSC markers in combination. (Uchida et al., 2000) induced tumors in immunocompromised mice (Singh et al., 2003; Singh et al., 2004) . In contrast to the CD133 + brain tumor cells, the CD133 -cells did not induce tumors, even when 10 5 cells were injected in the mice (Singh et al., 2004) . As well, CD133 + cells exhibited the self-renewal differentiation properties characteristic of CSCs (Singh et al., 2004) . Interestingly, as discussed later, CD133 would become a prominent CSC marker used for the isolation of highly tumorigenic cells in a number of cancers. However, like in other cancers, additional markers have been explored for brain cancer as well. Again taking cues from discoveries made from normal neural stem cell research, Ogdent et al. and Tchoghandjian et al. found that glioblastoma CSCs could be identified by increased expression A2B5 (Ogden et al., 2008; Tchoghandjian et al., 2010) . A2B5 is a ganglioside expressed specifically on the cell surface of neural progenitor cells (Nunes et al., 2003) . Unexpectedly, CD133 + and A2B5 + potentially identify separate populations of brain tumor cells that do not necessarily overlap, in a patient dependant manner. This finding challenges the CSC theory, which predicts the existence of a cancer initiating tumor cell population that is identifiable based on a universally expressed combination of markers. In 2007, Barraud et al. found that stage-specific embryonic antigen 4 (SSEA4), a known cell surface pluripotent human embryonic stem cell marker could also be used to enrich for the neural stem cells (Barraud et al., 2007) . Subsequently, Son et al. found that the same marker could be used to isolate brain tumor cells with the CSC phenotype (increased tumorigenicity, self-renewal/differentiation properties) (Son et al., 2009) . Almost all patient samples tested contained a SSEA4 + population, in agreement with the CSC theory (Son et al., 2009 ).
Prognostic correlation
As of yet ALDH activity has not been explored as a marker for the isolation of brain CSCs. Given its applicability in a number of cancers (as discussed above and below), it would be surprising to find that it is not a relevant brain CSC marker.
4b. Brain CSC markers as prognostic indicators
There have been a number of studies addressing prognostic applicability of the first brain/glioblastoma CSC marker identified, CD133 + (summarized in (Zeppernick et al., 2008) . The authors report that CD133 + prevalence and clustering was associated significantly with worse outcome and survival. Further, CD133 + was a risk factor for tumor regrowth and metastasis, independent of tumor grade. Later that year, Beier et al., quantified a set of 36 high grade oligodendroglial tumors (less than 10% of all neural cancers) for their CD133 positivity (Beier et al., 2008) . The authors reported that CD133 prevalence was a more accurate predictor of worse outcome for the patients than histological grading. In another 2008 study, Pallini et al. analysed a cohort of 44 glioblastoma patient tumor samples for prevalence of CD133 + and Ki67 + cells (Pallini et al., 2008) . While CD133+ expression alone failed to predict patient oucome, coexpression of CD133/Ki67 was a highly significant independent prognostic risk factor (Zhang et al., 2008) . The authors reported that CD133 + nestin + was associated with worse outcome and survival, and could potentially be used as independent prognostic indicators. Finally, in 2010, Sato et al. assessed if CD133 + prevalence was associated with spread of the cancer in glioblastoma (Sato et al., 2010) . The authors assessed 26 patient samples (16 cases of which the disease had disseminated) and reported that CD133 expression was significantly higher in disseminated disease cases. In summary, these studies agree that initial CD133 expression, especially when assessed in combination with an additional marker, is associated with more aggressive brain cancer and worse outcome. Therefore, the studies provide supportive evidence for the CSC theory postulation that CSCs are the initiators and mediators of cancers. We now await the results of studies evaluating the prognostic potential of the more recently discovered brain CSC markers (i.e. A2B5 and SSEA4) alone and in combination with CD133.
Most recently, the effect of therapy on the CSC population has been evaluated. In 2010, Pallini et al. quantified the frequency of CD133 pre and post radiochemotherapy on 37 paired glioblastoma patient samples (Pallini et al., 2010) . In support of the CSC theory that proposes CSCs are resistant to currently employed therapeutics, the researchers noted a significant increase (average 4.6 fold) in CD133 + cells post treatment. However, their analysis further revealed that the increased CD133 + frequency post treatment was surprisingly associated with improved survival, not worse. The authors' following experiments revealed that not all CD133 + cells quantified in the tumors were in actuality tumor cells. The non-tumor cell CD133 + population might potentially have confounded their assessment of CSC frequency pre and post treatment and the effect on patient survival (Pallini et al., 2010) . Furthermore, this revelation that not all CD133 + cells are tumor cells may explain their earlier results where CD133 + alone did not predict patient outcome, but CD133 + Ki67 + did (Pallini et al., 2008) . These results highlight the importance of employing multiple markers in the accurate identification of a CSC population in illustrating its potential prognostic applicability. (Dalerba et al., 2007) . The researchers showed that EpCAM + CD44 + colon cancer cells ranged from 0.03% to 38% (mean = 5.4%) of total colon cancer cells and were highly tumorigenic in immunocompromised mice. In addition, the authors identified another cell surface adhesion molecule, CD166, which could be used for the isolation of colon CSCs. CD166 could be used independently of EpCAM/CD44 or synergistically with these other two markers to further enrich for the CSC population. In 2008, Haraguchi et al. reported that CD133 + colon cancer varied in frequency from 0.3 -82.5% (mean 35.5%) and that the cancer initiating cell could be further enriched for by isolating cells that were positive for both CD133 and CD44 (Haraguchi et al., 2008) . CD133 + CD44 + colon cells were more tumorigenic than CD133 + or CD44 + isolated colon cancer cells. Interestingly, in 2009 another group showed that CD44 + isolated colon cells were highly tumorigenic, but failed to show similar tumorigenicity results when CD133 was used as the selection criterion (Chu et al., 2009 ). Spheroid cultured colon CSCs were analysed for their celluar antigen expression profile and were found to be positive for CD133, CD166, CD44, CD29, CD24, Lgr5 and nuclear β-catenin (Vermeulen et al., 2008) . All of these were previously known as normal colon stem cell markers, and some had been previously identified as colon CSC markers. The authors further showed that cells identified as CD133 + CD24 + were further enriched for CSCs, but that co-expression of the other identified cell surface markers (CD44, CD166, or CD29) with CD133 failed to further enrich for the CSC population.
Prognostic correlation
With the identification that ALDH activity could be used to isolate breast CSCs (Ginestier et al., 2007) , ALDH activity was also assessed as a CSC marker for other solid tumors, including colon cancer. Colon cancer cells isolated based on increased ALDH activity by the aldefluor assay were shown to be more tumorigenic by a number of groups (Carpentino et al., 2009; Chu et al., 2009; Huang et al., 2009 ). Huang et al. first showed that as few as 25 ALDH + colon cancer cells could induce tumors in immunocompromised mice, and suggested that ALDH activity may be a more stringent selection marker than CD133 or CD44 for the selection of a colon CSC population . Undoubtedly, future studies will reveal if ALDH + combined with expression of these cell surface molecules will lead to further enrichment of the colon CSC population.
5.b Colon CSC markers as prognostic indicators
The data evaluating the use of currently known colon CSC markers as prognostic indicators is mixed and summarized in Table 4 . For example, CD133 expression analyses are plentiful and do not reflect the molecule's prognostic value. We will first review the positive studies. In 2008, Horst et al. performed an immunohistological study of 77 fixed patient tumor samples and found that increased CD133 expression was indicative of worse outcome for patients (Horst et al., 2008) . Later in 2009, the same group assessed if expression of CD133 combined with β-catenin had significant prognostic value in a panel of 162 patient samples (Horst et al., 2009a) . CD133 and b-catenin stained distinct, partially overlapping cell populations and increased percentages of CD133 + b-catenin + was a stronger predictor of poor outcome than either marker alone (Horst et al., 2009a) . The same group also compared the prognostic value of colon CSC markers CD133, CD44 and CD166 together and alone in a panel of 110 colorectal adenocarcinomas (Horst et al., 2009b) . CD133 had the best prognostic potential of the three markers and correlated significantly with worse outcome (Horst et al., 2009b) . However, patients with increased CD133 + CD44 + CD166 + tumor cells fared the worse, illustrating again the value of using the markers in combination. In a study by another group, CD133 expression was quantified in 189 colorectal carcinomas and was predictive of worse outcome when specified to patients with well-and moderately-differentiated adenocarcinomas (Kojima et al., 2008) . In a final example, increased CD133 expression in a panel of 104 stage IIIB colon carcinoma patient samples correlated with worse prognosis (Li et al., 2009) . In contrast to above described positive results, Choi et al. performed immunohistological assessments on 523 patient samples, that represented the complete range of histoclinical diagnoses, to determine the prognostic value of colon CSC markers CD133, CD44 and CD24 (Choi et al., 2009) . Interestingly while expression of CD adhesion molecules correlated with some of the histoclinical prognostic indicators, none were significant prognostic predictors of survival (Choi et al., 2009) , disagreeing with the findings of Horst et al. (Horst et al., 2008; Horst et al., 2009a; Horst et al., 2009b) . Specifically, the authors determined that CD133 expression correlated with stage, CD24 with degree of differentiation and CD44 with tumor size (Choi et al., 2009 ). In 2010, Lugli et al., failed to correlate increased CD133 expression with tumor progression or survival time of patients when they probed a large panel of 1420 colorectal cancers by tissue microarray (Lugli et al., 2010) . The cohort of samples was also probed for other implicated colon CSC markers; CD166, CD44 and EpCAM, and in contradiction of the CSC theory, their loss of expression, not gain, was associated with increased tumor progression and survival time. This trend was even more evident when the markers were combined (e.g. CD166 -CD44 -). Independent of the discoveries implicating CD44, CD166, and CD24 as potential colon CSC markers (Dalerba et al., 2007; Vermeulen et al., 2008) , the expression of the CD molecules has been previously assessed for predicting the outcome for colorectal cancer patients. For example, expression of certain splice variants of CD44 has been associated with worse outcome for colorectal cancer patients as early as the 1990s. In 1994, Mulder et al., stained 64 patient panel samples and for CD44v6 reported that increased expression of the CD variant was associated with increased tumor-related death (Mulder et al., 1994) . However, another study by Weg-Remers et al., failed to detect a correlation between expression of CD44, standard or variants, and patient outcome or tumor progression (Weg-Remers et al., 1998) . CD166 expression had been associated with reduced survival, despite not being correlative with tumor grade, stage or nodal involvement (Weichert et al., 2004) . The same group later stained a cohort of 147 colon cancer patient samples for CD24 expression and made the distinction between membrane and cytoplasmic CD24 (Weichert et al., 2005) . Interestingly, patients with high levels of cyoplasmic CD24 fared significantly worse, being more likely to have higher grade tumors, and develop metastases. Our analysis of the literature reveals a large disparity in the prognostic potential of the identified cell surface colon CSC markers. Potentially, differences in the results between groups could be explained by the varied methods and cut-offs used in tissue staining and scoring (Zlobec et al., 2007) . For example Choi et al. scored the stained tissue samples as either positive or negative for expression of the CD molecules, whereas in the studies by Horst et al., the degree of staining was graded as none, low or high (Choi et al., 2009; Horst et al., 2008; Horst et al., 2009a; Horst et al., 2009b) . Undoubtedly however, this can only be part of the explanation and it is more likely that the disagreement between groups is potentially an indication of the overall insignificant or poor prognostic value of these CSC markers for colon cancer when employed alone.
Prognostic correlation
With the 2009 discovery that ALDH activity is also specific to colon CSCs (Carpentino et al., 2009; Chu et al., 2009; Huang et al., 2009) , the potential of ALDH1A1 as a prognostic indicator is also being evaluated. In the recent study by Lugli et al., described above, who probed a panel of 1420 colorectal carcinomas for currently known cell surface colon CSC markers, the authors also assessed if ALDH1A1 expression had prognostic value (Lugli et al., 2010) . The researchers detected ALDH1A1 in less than 25% of samples and failed to correlate patient outcome or disease progression with expression of the protein. Increased ALDH1A1 expression did however correlate with tumor grade (Lugli et al., 2010) . In the coming years, the results of more immunohistological studies will clarify the potential prognostic power of ALDH1A1 for colorectal cancer.
Prostate cancer 6.a Identified prostate CSC markers
The currently known prostate CSC markers are based on the unique cell surface molecules and functional characteristics of normal prostate stem cells. Combining previously identified prostate stem cell markers CD44 + , α2β1 high , CD133 + , Collins et al. isolated prostate cancer cells from patient tumor samples that had the in vitro self-renewal and differentiation properties of CSCs (Collins et al., 2005) . Later in 2006, Patrawala isolated CD44 + prostate cancer cells from cultures and tumors and showed that these cells possessed increased tumorigenicity in vivo and had stem cell like qualities (Patrawala et al., 2006) . In 2005, using a murine prostate cancer model, Xin et al. showed that prostate cancer cells expressing stem cell antigen-1 (sca-1) were comparatively highly tumorigenic and possessed stem cell like characteristic (Xin et al., 2005) . More recently, ALDH activity was also explored as a CSC marker for prostate cancer (Li et al., 2010b; van den Hoogen et al., 2010) . Prostate cancer cells with increased ALDH activity were highly tumorigenic and possessed stem cell like characteristics (Li et al., 2010b; van den Hoogen et al., 2010) . Interestingly, ALDH + cancer cells were also positive for CD44 and α2β1 integrin, but not CD133 (van den Hoogen et al., 2010) .
6.b Prostate CSC markers as prognostic indicators
The prognostic potential of currently known prostate CSC markers is ambiguous at best at this time (summarized in Table 5 ). CD44 has been assessed as a prognostic marker for prostate cancer since the 1990's, long before it was identified as a prostate CSC marker (Patrawala et al., 2006) . In 1996, Nagabhushan et al. quantified the prevalence of CD44 in 74 fixed prostate cancer patient samples and noted that CD44 expression correlated inversely with tumor grade (Nagabhushan et al., 1996) . A similar inverse relationship was detected in a subsequent study (Noordzij et al., 1997) . Then again, 1999 and 2000, the same group published that CD44 expression decreased in patients with metastatic disease (Noordzij et al., 1999) and the loss of CD44 expression was an independent prognostic predictor of clinical reoccurrence (Vis et al., 2000) . In 2001, Aaltomaa et al. analysed 209 prostate cancer samples and found that decreased CD44 expression correlated with metastasis and worse outcome (Aaltomaa et al., 2001 ). The results of these studies are in clear agreement with the prognostic potential of CD44 for prostate cancer. Unfortunately, from a CSC point of view, they are opposite to the predictions of the CSC theory, whereby an increase in CD44 would be expected to be associated with worse, not better outcomes.
The recent discoveries that ALDH activity could be employed to isolate prostate CSCs were also accompanied by prognostic data. van den Hoogen et al., failed to detect ALDH1A1 in 30 tissue microarray samples and 10 fixed primary tumor samples (van den Hoogen et al., 2010) . The authors then decided to evaluate if expression of some of the other ALDH isoforms correlated significantly with clinical pathological determinants. While expression of isoform ALDH7a1 was detected in the majority patient samples, its expression failed to correlate significantly with Gleason score or tumor grade. These findings are in contrast to results published by Li et al. who report that increased ALDH1A1 expression correlated significantly with Gleason score, disease stage, and worse survival (Li et al., 2010b) . Future immunohistological studies should resolve the discrepancy between the two groups with regards to the prognostic importance of ALDH1A1.
The greater prognostic potential of employing the CSC markers in combination remains to be shown for prostate cancer. Collins et al. who first discovered that the approximate 0.1%of CD44 + α2β1 high CD133 + of all prostate tumor cells had stem cell like characteristics, also reported that prevalence of these potential CSCs did not correlate with tumor grade (Collins et al., 2005) . Perhaps future studies combining cell surface and functional markers (e.g. ALDH activity) may reveal a potential prognostic role for prostate CSC markers. . This work provided the first indication that CD133 could potentially be used as a lung CSC marker. Later in 2009, Bertolini et al. proved that CD133 was a lung CSC marker (Bertolini et al., 2009 ). The researchers showed that patient isolated CD133 + (and stained with epithelialspecific antigen to eliminate contaminating cells) lung cancer cells were highly tumorigenic compared to CD133 -cancer cells and had stem cell characteristics (Bertolini et al., 2009) . Similar results using CD133 as a lung CSC marker were published by another group later that year, solidifying CD133's recognition as an important lung CSC marker (Tirino et al., 2009) .
Prognostic correlation
ALDH activity has also been tested for the isolation of lung CSCs (Jiang et al., 2009; Ucar et al., 2009 ). Jiang et al. showed it was possible to isolate ALDH + lung cancer cells from cultured cell lines that were more tumorigenic in immunocompromised mice and displayed stem cell like qualities (i.e. self renewal/differentiation and resistance to chemotherapeutics). As of yet ALDH activity and CD133 have not been employed in combination to potentially isolate a further CSC-encriched population of cells.
7.b Lung CSC markers as prognostic indicators
The data evaluating the use of currently known lung CSC markers as prognostic indicators is mixed and summarized in Table 6 . In addition to illustrating the increased tumorigenicity of CD133 + lung cancer cells, Bertolini et al., assessed if CD133 had prognostic value for lung cancer patients (Bertolini et al., 2009) . The researchers stained a panel of 42 fixed tumor samples for CD133 expression and showed that patients with CD133 + tumors tended to have a shorter progression-free survival. However, the outcome difference between CD133 + and CD133 -tumors was not statistically significant. Tirino et al. also evaluated the prognostic potential of CD133 for lung cancer (Tirino et al., 2009) . Their study of 89 patient samples failed to find a correlation between CD133 expression and the clinical pathological assessments of disease aggressiveness (e.g. tumor size, stage). However they noted a nonsignificant trend toward shorter disease progression times in the CD133 + patient samples. In a another study of 88 patient samples conducted by Salnikov et al., CD133 + prevalence failed to significantly correlate with tumor size, cancer stage, local metastasis or overall survival (Salnikov et al., 2010) . Potentially if a larger sample size was employed in the studies statistical significance may have been reached for some parameters. The above studies suggest that presence of CD133 alone does not appear to be a strong predictor of disease progression and outcome for lung cancer. However, recent studies employing CD133 in combination with other markers appear more promising. In 2010, Li et al. showed that combination of CD133 with the ABC transporter, ABCG2, was a much more powerful prognostic tool than either marker alone (Li et al., 2010a (Jiang et al., 2009 ). ALDH1A1 expression correlated significantly with higher tumor grade, disease stage and poor clinical outcome (Jiang et al., 2009) . Interestingly, in these immunohistochemical analyses ALDH1A1 positive samples were also CD133 + (60% of patient samples). In contrast, patient samples that were negative for ALDH1A1 expression also lacked CD133 expression. This suggests that potentially CD133 + and ALDH + can be combined to isolate a more tumorigenic population of lung cancer cells. Future studies will reveal if CD133 combined with ALDH1A1 is a superior and potentially powerful prognostic tool for lung cancer. 
Prognostic correlation
Conclusions
CSCs have become a universal cancer concept. Using in vitro and in vivo experimental models, this sub-population of highly tumorigenic tumor cells has been shown to exist in most cancers and is resistant to chemo-and radiation therapy. As such, CSCs are believed to be the initiators of cancer, propagators of metastasis and mediators of therapeutic resistance. What is needed is conclusive proof of the importance of CSCs from clinical patient data. As reviewed here, there already exists much clinical data that support or refute the CSC theory from a cancer progression and reoccurrence point of view. Based on publised data thus far, it appears that using a combination of CSC markers, and eliminating the least relevant proposed CSC markers, is the most logical approach not only for accurate identification of CSCs but also for revelation of their important roles in cancer development. With the inevitable future discovery of new CSC markers and their combined use with valid ones previously discovered, the empirical proof that CSCs are the key to both the cause and cure of cancer may be a foregone conclusion.
